Immunohistochemical analysis of Estrogen Receptor beta in paraffin-embedded human breast carcinoma using an Estrogen Receptor beta monoclonal antibody (Product # MA1-27412) following antigen retrieval with EDTA. Detection was performed with a Histar detection kit.
|Tested species reactivity||Human, Non-human primate|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Synthetic peptide corresponding to the C-terminal domain of human oestrogen receptor beta 1 isoform.|
|Storage buffer||tissue culture supernatant|
|Contains||0.1% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:20|
|Immunohistochemistry (Paraffin) (IHC (P))||1:20|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-27412 detects Estrogen Receptor beta from human and New World primate samples.
MA1-27412 has been successfully used in immunohistochemistry (Frozen and paraffin) procedures. Positive control of ovary suggested.
The MA1-27412 immunogen is a synthetic peptide corresponding to the C-terminal domain of human oestrogen receptor beta 1 isoform.
Store at 4°C or -20°C if preferred. Avoid freeze/thaw cycles.
The human ER-beta is a newly discovered estrogen receptor initially cloned and characterized from testis. The size and structure of ER-beta is very similar to ER-alpha with the ligand and DNA binding domains being highly conserved, while the amino terminus which serves as their transactivation domain has diverged significantly. Similar in function to ER-alpha ER-beta binds to estrogen with a high affinity and regulates estrogen specific gene activation through direct interaction with estrogen response elements (ERE's).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
ERß expression and breast cancer risk prediction for women with atypias.
MA1-27412 was used in immunohistochemistry - paraffin section to assess ERbeta expression in breast cancer tissues
|Hieken TJ,Carter JM,Hawse JR,Hoskin TL,Bois M,Frost M,Hartmann LC,Radisky DC,Visscher DW,Degnim AC||Cancer prevention research (Philadelphia, Pa.) (8:1084)||2015|
The Estrogen Pathway: Estrogen Receptor-¿, Progesterone Receptor, and Estrogen Receptor-ß Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens.
MA1-27412 was used in immunohistochemistry to discuss the role of the estrogen pathway in bladder cancer development.
|Tan W,Boorjian S,Advani P,Farmer S,Lohse C,Cheville J,Kwon E,Leibovich B||Clinical genitourinary cancer (13:476)||2015|
Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women.
MA1-27412 was used in immunohistochemistry - paraffin section to discuss the contributions of cigarette smoking, hormone therapy, and folate intake to colon cancer.
|Tillmans LS,Vierkant RA,Wang AH,Samadder NJ,Lynch CF,Anderson KE,French AJ,Haile RW,Harnack LJ,Potter JD,Slager SL,Smyrk TC,Thibodeau SN,Cerhan JR,Limburg PJ||Cancer epidemiology, biomarkers and prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (24:713)||2015|
ERß1: characterization, prognosis, and evaluation of treatment strategies in ER¿-positive and -negative breast cancer.
MA1-27412 was used in immunohistochemistry - paraffin section to characterize ER-beta1 as a treatment strategy for prognosis and evaluztion in ER-alpha positive and negative breast cancer
|Reese JM,Suman VJ,Subramaniam M,Wu X,Negron V,Gingery A,Pitel KS,Shah SS,Cunliffe HE,McCullough AE,Pockaj BA,Couch FJ,Olson JE,Reynolds C,Lingle WL,Spelsberg TC,Goetz MP,Ingle JN,Hawse JR||BMC cancer (14:null)||2014|